A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies

BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit. This is a multi-center, open-label, single-arm Phase Ib/II clinical study. The purpose of this clinical trial is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of Rocbrutinib, a fourth-generation Bruton tyrosine kinase inhibitor (BTKi), in combination with the BCL-2 inhibitor Lacutoclax in patients with mature B-cell malignancies. The Phase Ib will use a classic 3+3 dose-escalation

Trial Details

NCT ID
NCT07609862
Phase
PHASE1 / PHASE2
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Status
RECRUITING
Cancer Type
Mantle Cell Lymphoma Lymphoma
Interventions
  • Lacutoclax+Rocbrutinib
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Age ≥18 years, regardless of sex.
  • Ib: Histologically confirmed diagnosis of CLL/SLL (per 2018 iwCLL criteria) or B-cell malignancies (per 2022 WHO classification), including: MCL, D…
  • II: For Treatment-naïve (TN) CLL/SLL patients: Must meet iwCLL treatment indications and no prior systemic therapy. For R/R CLL/SLL patients: at le…
  • Have at least one measurable lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mantle Cell Lymphoma Lymphoma Trials on Trialify →